Reginald Seeto: Yes. No, Mark, it’s a great question. I mean, historically, we’ve always done anywhere from 1 to 3 acquisitions a year, that’s — these are small bolt-ons consistent with our HLA data systems. We have a unique ability to find smaller opportunities that really can add either to the moat or add such in the case of Transplant Pharmacy to some of the top line. So we feel good about these opportunities because every one of them, people have come to us. It hasn’t been one where we’ve had to slice it out. I mean we get so many inbounds, but it’s really finding those that can drive leadership mark. So those are going to be one and two. It doesn’t really make sense to get in where it’s still nascent or one where it’s not going to be in a leadership position.
So that’s probably one of the key things I think always one is to look across the board for opportunities, but also which makes sense for us as an organization. I mean, we’re committed to the transplant space. So I think there’s a fine number of opportunities. And again, we get these on a very routine basis. And we assess them with a lot of rigor. So again, we’re excited by the year ahead, greatly being this financial position and able to deploy our capital in the appropriate ways we have done historically.
Mark Massaro: Okay. And then any update on RemoTraC or mobile phlebotomy?
Reginald Seeto: No, nothing significant change there, Mark.
Mark Massaro: Okay, guys thanks for all the questions.
Reginald Seeto: Thank you again.
Operator: Our next question is from Yi Chen with H.C. Wainright. Please proceed.
Yi Chen: Thank you for taking my question. My first question is, is there additional room for cash collection improvement?
Reginald Seeto: Yes. As we mentioned, this is an area that we’ll start sharing quarterly pace of chain. And I think what we’ve signaled is that we expect the cash collections to exceed the testing services revenues as we now play a bit of catch-up with, for example, some of the delayed processes and collections of past such as Medicare Advantage and also as we also add more commercial pay coverage on a regional basis. So there’s certainly the opportunity and we’ll compare this year-over-year for you and provide that metric.
Yi Chen: Yes. Okay. And when do you expect to generate meaningful revenue from cell therapy monitoring?
Reginald Seeto: Yes, it’s an excellent question. I mean I think for us, we’ve always signaled that our cell therapy franchise, whether AlloSure or talking about some of the other — some other offerings we have, it’s something probably more on the greater the 5-year horizon. The reason we say that is because it’s really predicated on having the actual cell therapies make it to market, and as a date in the U.S., none of the allogeneic cell therapies have made it to market. So there’s a lot of activity, preclinical Phase I, Phase II, — but unfortunately, no one’s got over the line yet. And so we look forward to those in the future. And now our goal now is to be very early in that process to develop those research and clinical partnerships so that we can be there once this transformative type of opportunity makes it to critical scale and mass. So similar to what we’ve done with our approach in the solid organ space.
Yi Chen: Got it. And lastly, maybe you touched upon this before. What evidence have you observed that make you feel confident the number of living donors will actually rebound in the coming quarters or years?
